| Customization: | Available |
|---|---|
| CAS No.: | 14605-22-2 |
| Formula: | C26h45no6s |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Hunan Yunbang Pharmaceutical Co., Ltd. (Yunbangpharm) located in Changsha High-tech Industrial Park, Hunan. It is a high-tech enterprise specializing in the research and development, production and sales of Pharmaceutical raw materials, Pharmaceutical intermediates(API) and Fine chemicals. Based in China, Yunbangpharm has been providing suitable solutions for many domestic,foreign pharmaceutical companies and traders. Excellent quality, good reputation and authentic price have won the praise of the majority of customers.
1:Can I get some samples before bulk order?
A: Most products provide free samples, but the shipping cost be paid by customers.
2: What's your MOQ?
A: We can have a discussion.
3: Which kind of payment terms do you accept?
A: PI will be sent first after confirmation of order,enclosed our bank information.Payment by T/T, Western Union,D/P, ETC.
4.How to place an order?
A: You can contact me through Trademanager, WhatsApp, Email and other contact methods, tell me the product and quantity you need, and then we will give you a quote.
5:How about your delivery time?
A: Generally, it will take 3 to 5 days after receiving your advance payment.
6:How do you treat quality complaint?
A: First of all, our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss.
| Product Name: | Tauroursodeoxycholic acid |
| Synonyms: | ursodeoxycholyltaurine;yl)amino)-;3a,7b-Dihydroxy-5b-cholan-24-oic Acid N-(2-Sulfoethyl)amide;Ursodeoxycholyltaurin;3α,7β-dihydroxy-5β-cholan-24-oic acid n-(2-sulfoethyl)amide;TUDCA Soduim Salt;TAUROURSODEOXYCHOLIC ACID DIHYDRATE: 90%;tauroursodeoxycholic acid sodium |
| CAS: | 14605-22-2 |
| MF: | C26H45NO6S |
| MW: | 499.7 |
| EINECS: | 1308068-626-2 |
| Product Categories: | Miscellaneous Natural Products;Bile Acids;Biochemistry;Steroids;Chiral Reagents;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Herb extract;14605-22-2 |
| Mol File: | 14605-22-2.mol |
| Melting point | 173-175°C |
| density | 1.216±0.06 g/cm3(Predicted) |
| refractive index | 46 ° (C=1, EtOH) |
| storage temp. | 15-25ºC |
| solubility | Soluble in DMSO (up to 30 mg/ml) or in Ethanol (up to 20 mg/ml with warming) |
| pka | 1.42±0.50(Predicted) |
| form | solid |
| color | White |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month. |
| InChIKey | BHTRKEVKTKCXOH-LBSADWJPSA-N |
| SMILES | [C@@]12([H])CC[C@H]([C@H](C)CCC(=O)NCCS(=O)(=O)O)[C@@]1(C)CC[C@]1([H])[C@@]3(C)CC[C@@H](O)C[C@@]3([H])C[C@H](O)[C@@]21[H] |&1:0,4,5,18,22,24,28,31,34,36,r| |
| CAS DataBase Reference | 14605-22-2(CAS DataBase Reference) |
| Safety Statements | 22-24/25 |
| WGK Germany | 2 |
| RTECS | KI7372500 |
| HS Code | 29242990 |
| Toxicity | mouse,LD50,intravenous,350mg/kg (350mg/kg),Japanese Kokai Tokyo Koho Patents. Vol. #92-235918, |
| Mode of action | Tauroursodeoxycholic acid is the more hydrophilic form of ursodeoxycholic acid, which is naturally produced in the body. In patients with properly functioning gallbladders, both of these bile acids inhibit liver cholesterol secretion and synthesis as well as intestinal cholesterol absorption allowing for the promotion of cholesterol gallstone dissolution. The main mechanisms supporting possible Neuroprotective effects of TUDCA include the prevention of apoptosis. Specifically, TUDCA has been shown to inhibit apoptosis by modulating mitochondrial membrane perturbation and pore formation, B cell lymphoma 2[Bcl-2]-associated protein X(BAX) translocation, cytochrome c release, and caspase activation[11]. TUDCA inhibits amyloid beta[Ab]-induced apoptosis and attenuates the endoplasmic reticulum(ER) stress, which are thought to be key components of the pathological process in certain diseases[12,13]. |
| Pharmacological effects | TUDCA inhibits apoptosis Studies have shown that TUDCA is active in multiple steps of the apoptotic pathway. Apoptosis plays a crucial role in maintaining homeostasis, in physiological processes, and in many diseases[14]. TUDCA acts to inhibit apoptosis by modulating both the extrinsic and intrinsic pathways of apoptosis, activating cAMP response element-binding protein(CREB), and initiating cell survival pathways. In early studies of TUDCA and its cytoprotective effects, it was shown that TUDCA prevents release of cytochrome c, cytosolic caspase activation, and cleavage of the nuclear enzyme PARP to halt the apoptotic pathway[15]. In addition, a study published in 2000 showed that TUDCA prevents the depolarization of the mitochondrial membrane and the translocation of BAX from the cytosol[16]. TUDCA is equally effective at reducing p53-induced apoptosis and modulating the expression of Bcl-2[17]. P53 upregulates apoptotic proteins such as BAX and apoptotic protease-activating factor 1(Apaf-1), so by inhibiting p53 TUDCA can control the action of various other proteins involved in the mitochondrial pathway. TUDCA can also inhibit the action of caspase 2, 3, 6, and 9 either directly or indirectly helping to stop caspase-dependent apoptosis[18]. TUDCA modulates Amyloid-beta-induced apoptosis Aβ peptide is implicated in the pathogenesis of neurological diseases such as Alzheimer's, where there is a loss of neuronal cells through the process of apoptosis[19]. Aβ causes significant induction of apoptosis in cortical neurons and is associated with a translocation of pro-apoptotic BAX to the mitochondria[20]. TUDCA modulates this event and the subsequent steps of cytochrome c release, caspase activation and DNA/Nuclear fragmentation. It also inhibits Aβ peptide-induced apoptosis via modulation of the PI3K signaling cascade and regulation of the E2F-1/ p53/BAX pathway[21]. Moreover, TUDCA counteracts Aβ-induced apoptosis through interaction with the mineralocorticoid receptor(MR), which is an inhibitor of apoptosis[22]. MR decreases p53 levels and changes the ratio of pro-relative to anti-apoptotic Bcl-2 members. TUDCA targets a region of MR ligand binding domain and dissociates the nuclear steroid receptor(NSR) from heat shock protein-90. From here, the TUDCA/NSR complex translocates to the nucleus and modulates NSR activity, where it reduces Aβ-induced apoptosis. TUDCA modulates ER stress The ER plays an important role in regulating cellular responses to stress[23]. The ER reads and integrates apoptotic signals and can initiate an ERS mediated pathway to apoptosis. Accumulation of unfolded proteins in the ER induces ERS. This accumulation of mis-folded proteins leads to the unfolded protein response(UPR), which can either cause the cell to undergo apoptosis or to fix the unfolded proteins and restore balance. TUDCA has been shown to inhibit ERS and block the UPR before it needs to be initiated. PERK[PKR[RNA-dependent kinase]-like ER kinase] is a part of the UPR[24]. TUDCA activates PERK which leads to the inactivation of eukaryotic translation initiation factor 2(EIF2). This causes a reduction in protein synthesis, halting aggregation of mis-folded proteins. Any proteins left over are degraded through autophagy. TUDCA modulates protein kinase C TUDCA is a significant calcium agonist and induces a sustained increase in free Ca2+ ions[25]. Inositol 1,4,5-triphosphate-sensitive calcium stores are modulated by TUDCA, causing a calcium influx across the plasma membrane via calcium ion channels[26]. Influx of calcium across the hepatocellular membrane via Ni-sensitive calcium channels and intracellular calcium oscillations plays a role in vesicular exocytosis. Protein kinase C(PKC) helps to control calcium influx and secretory events, as well as stimulating biliary exocytosis[27]. Translocation of PKC occurs by a calcium-dependent manner and binding of membrane phospholipid cofactors, such as phosphatidylserine(PS). In addition, activation of PKC occurs by binding of diacylglycerol to the Ca-PKC-PS complex. TUDCA activates membrane-associated PKC and increases its activity of reducing ischemic damage and increasing secretory events[26]. TUDCA's effect on hepatocellular calcium with subsequent involvement in the activation of PKC shows that TUDCA activates complex patterns of signals in hepatocytes to increase apical membrane exocytosis. |
| Therapeutic applications of TUDCA | Myocardial Infarction TUDCA may prove to be an effective treatment in patients suffering from a heart attack. Rivard et al.[29] conducted a study on the effect of TUDCA following MI in rats. The authors tested whether administering TUDCA to rats prior to an MI would improve cardiac function. TUDCA was administered prior to ligation of the left anterior descending coronary artery. TUNEL and caspase-3 activity were assessed 24 h post-injury to detect apoptosis. TUNEL labeling showed a reduction in apoptotic cells, and caspase-3 activity was significantly reduced in rats given TUDCA prior to ischemic heart injury. At 4 weeks post-injury, TUDCA-administrated rats showed a significantly smaller infarct area in the myocardium compared to the control. The TUDCA group also showed improvement in shortening fraction assessed via ultrasound. The authors concluded that TUDCA could be a viable option for reducing apoptosis in MI. Hemorrhagic Stroke Intracerebral hemorrhage(ICH) is a serious injury with incidence of 24.6 cases per 100,000 person years(with 30-day and 1-year mortality rates of 40 and 54 %, respectively)[30]. Only 12-39 % of patients with ICH achieve long-term functional independence[30]. Recent work has shown that apoptosis is a major pathological process in ICH, and apoptotic-inhibiting therapies may provide a new approach to treatment. Caspase-3 levels are raised during ICH and DNA fragmentation occurs, both markers for apoptosis[31]. Researchers have hypothesized treatment of ICH with TUDCA since it is a potent apoptosis inhibitor. Rodrigues et al.[32] determined that TUDCA reduces apoptosis and protects neurons from acute hemorrhagic stroke in a rat model of ICH. TUDCA was administered 1 h before, 1 h after, or 3 h after the ICH onset. The authors showed that TUDCA administered at all time points in the study reduced lesion volumes at 2 days by as much as 50 % and apoptosis was decreased by 50 % in the perihematoma regions. Rotational symmetry, limb placement, and stepping ability, markers to assess neurobehavioral deficits were improved in the treated groups. TUDCA modulated Bcl-2 expression, activated the AKt-1/protein survival pathway, and induced BAD phosphorylation. Akt phosphorylates BAD and blocks BAD-induced death of primary neurons[33]. They concluded that TUDCA was promising in the treatment of hemorrhagic stroke due to its neuro-protective effects and safe clinical use. Ischemic Stroke During hypoxic ischemia, cell death occurs via apoptosis and necrosis. There is an overexpression of BAX in tissue following focal ischemia, indicating increased levels of apoptosis[34]. Caspase inhibitors have been shown to be neuro-protective in rat models of hypoxic-ischemic brain injury demonstrating a role of apoptosis in ischemia-related injuries[35]. Hypotheses behind this phenomenon are that damage created by ischemia induces apoptosis if ischemia is prolonged and necrosis occurs. Treatments inhibiting apoptosis could show promise in improving outcomes from ischemia-related diseases and others listed above[14]. In fact, Endres et al.[36] showed that inhibitors of apoptosis, specifically caspase inhibitors, reduce brain damage after middle cerebral artery occlusion. Other Neurological and Non-neurological Diseases Neuroprotective effects of TUDCA in preclinical studies of Huntington's disease(HD) have shown to significantly reduce striatal neuropathology in the transgenic mice model of HD mouse[37]. TUDCA has also shown to suppress Aβ-induced apoptosis in multiple models of Alzheimer's disease(AD). In Parkinson's disease(PD), the loss of neurons is mainly mediated by apoptosis triggered by mitochondrial dysfunction and increase in reactive oxygen species(ROS). TUDCA was demonstrated to have a beneficial role in survival and function of nigral transplant in a rat model of PD[38] and also to partially rescue mitochondrial dysfunction in genetic PD models in Caenorhabditis elegans[39]. Recently, TUDCA has been shown to be safe and potentially effective in the treatment of Amyotrophic Lateral Sclerosis or ALS(Amyotrophic lateral sclerosis). |
| References |
|
| Description | Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid synthesized in hepatocytes by the conjugation of ursodeoxycholic acid (UDCA) with the amino acid taurine. UDCA, which is made by gut bacteria, is FDAapproved in the United States for the treatment of certain cholestatic liver diseases. Humans make TUDCA to some extent, but it is found in copious amounts in the bile of bears. TUDCA is a classic inhibitor of endoplasmic reticulum (ER) stress. Reduces ER stress and adipose tissue inflammation in a mouse model of high fat diet-induced obesity. Blocks ER stress-induced NLRP3 inflammasome activation and hepatocyte death. Attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mouse model. |
| Chemical Properties | Tauroursodeoxycholic acid is an off-White Solid. It is an ambiphilic bile acid. It is mainly found in black bear bile, which is the signature active ingredient in bear bile. It has antispasmodic, anticonvulsant, anti-inflammatory and gallstone dissolving effects. |
| Uses | Tauroursodeoxycholic acid (TUDCA) is a water-soluble bile salt naturally occurring in the body. When bile salts reach the intestines, they can be metabolized by bacteria into ursodeoxycholic acid (UDCA). TUDCA is formed when taurine binds to UDCA. TUDCA is used to treat cholestasis, a condition in which bile fails to flow from the liver to the duodenum. TUDCA, UDCA, and other soluble bile salts can counteract the toxicity of regular bile acids when the latter are backed up in the liver. TUDCA is also used to treat cholesterol gallstones, dissolving them to a size in which they may be passed. |
| Definition | ChEBI: Tauroursodeoxycholic acid is a bile acid taurine conjugate derived from ursoodeoxycholic acid. It has a role as a human metabolite, an anti-inflammatory agent, a neuroprotective agent, an apoptosis inhibitor, a cardioprotective agent and a bone density conservation agent. It derives from an ursodeoxycholic acid. It is a conjugate acid of a tauroursodeoxycholate. |
| Side effects | TUDCA is safe and well-tolerated in patients with liver transplants, liver cirrhosis, and other diseases, but no clinical data exist for treatments longer than 1 year. There were no significant differences in adverse events between those receiving standard immunosuppressants versus those receiving bile acids in addition. Other trials in liver cirrhosis (up to 6 months) and ALS (1 year) have also reported that TUDCA is well-tolerated with diarrhea being the only side effect (Elia et al., 2016; Ma et al., 2016; Pan et al., 2013; Crosignani et al., 1996). Tauroursodeoxycholic-Acid-Cognitive-Vitality-For-Researchers |
| Mode of action | Tauroursodeoxycholic acid is a bile acid taurine conjugate derived from ursodeoxycholic acid. Bile acid is made by the liver and stored in the gallbladder and helps with digestion. It has a role as a human metabolite, an anti-inflammatory agent, a neuroprotective agent, an apoptosis inhibitor, a cardioprotective agent and a bone density conservation agent. TUDCA is found in small quantities in human bile but at a higher concentration in the bile of black bears, which is the signature active ingredient in bear bile. It demonstrates anti-apoptotic activity in rodent models of tauopathy, Huntington's disease, ischemic brain injury, and retinal disorders. |
| References | 1) Xie?et al.?(2002),?Effects of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation; Hepatology,?36?592 2) Chen?et al.?(2016),?Chemical chaperones reduce ER stress and adipose tissue inflammation in high fat diet-induced mouse model of obesity; Sci. Rep., 6?27486 3) Lebeaupin?et al. (2015),?ER stress induces NLRP3 inflammasome activation and hepatocyte death; Cell Death Dis.,?6?e1879 4) Nunes?et al.?(2012),?TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mice; Mol. Neurobiol.?45?440 |
){kind=link}